Free Trial
→ The SpaceX supplier that shipped 5 billion chips to Starlink (From Weiss Ratings) (Ad)tc pixel Free GNCA Stock Alerts

Genocea Biosciences (GNCA) Competitors

Genocea Biosciences logo
Compare

GNCA vs. SCPS, ORGS, VAXX, ARDS, and TRVN

Should you buy Genocea Biosciences stock or one of its competitors? MarketBeat compares Genocea Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genocea Biosciences include Scopus BioPharma (SCPS), Orgenesis (ORGS), Vaxxinity (VAXX), Aridis Pharmaceuticals (ARDS), and Trevena (TRVN). These companies are all part of the "pharmaceutical products" industry.

How does Genocea Biosciences compare to Scopus BioPharma?

Scopus BioPharma (NASDAQ:SCPS) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

0.6% of Genocea Biosciences shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Scopus BioPharma has a beta of -0.17, meaning that its share price is 117% less volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market.

Scopus BioPharma's return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
Genocea Biosciences N/A -182.88%-62.76%

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
Genocea Biosciences Neutral

Scopus BioPharma has higher earnings, but lower revenue than Genocea Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A

Summary

Scopus BioPharma beats Genocea Biosciences on 4 of the 7 factors compared between the two stocks.

How does Genocea Biosciences compare to Orgenesis?

Genocea Biosciences (NASDAQ:GNCA) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Genocea Biosciences has a beta of 1.61, indicating that its share price is 61% more volatile than the broader market. Comparatively, Orgenesis has a beta of 3.06, indicating that its share price is 206% more volatile than the broader market.

Genocea Biosciences has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
Orgenesis -3,827.81%N/A -130.18%

Genocea Biosciences has higher revenue and earnings than Orgenesis. Orgenesis is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
Orgenesis$662K4.61-$55.36M-$11.51N/A

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Orgenesis Neutral

0.6% of Genocea Biosciences shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by insiders. Comparatively, 1.9% of Orgenesis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Genocea Biosciences beats Orgenesis on 6 of the 10 factors compared between the two stocks.

How does Genocea Biosciences compare to Vaxxinity?

Genocea Biosciences (NASDAQ:GNCA) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

Genocea Biosciences has higher revenue and earnings than Vaxxinity. Vaxxinity is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
VaxxinityN/AN/A-$56.93M-$0.45N/A

In the previous week, Vaxxinity had 1 more articles in the media than Genocea Biosciences. MarketBeat recorded 1 mentions for Vaxxinity and 0 mentions for Genocea Biosciences. Genocea Biosciences' average media sentiment score of 0.00 equaled Vaxxinity'saverage media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Vaxxinity Neutral

Genocea Biosciences has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market. Comparatively, Vaxxinity has a beta of -74.37, suggesting that its stock price is 7,537% less volatile than the broader market.

Vaxxinity's return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
Vaxxinity N/A N/A N/A

0.6% of Genocea Biosciences shares are held by institutional investors. Comparatively, 82.9% of Vaxxinity shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by insiders. Comparatively, 64.1% of Vaxxinity shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Vaxxinity beats Genocea Biosciences on 7 of the 10 factors compared between the two stocks.

How does Genocea Biosciences compare to Aridis Pharmaceuticals?

Genocea Biosciences (NASDAQ:GNCA) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

Aridis Pharmaceuticals' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
Aridis Pharmaceuticals N/A N/A N/A

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Aridis Pharmaceuticals Neutral

Aridis Pharmaceuticals has lower revenue, but higher earnings than Genocea Biosciences. Genocea Biosciences is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
Aridis PharmaceuticalsN/AN/A-$30.37M$0.090.02

0.6% of Genocea Biosciences shares are owned by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Genocea Biosciences has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 49.37, suggesting that its stock price is 4,837% more volatile than the broader market.

Summary

Aridis Pharmaceuticals beats Genocea Biosciences on 8 of the 9 factors compared between the two stocks.

How does Genocea Biosciences compare to Trevena?

Genocea Biosciences (NASDAQ:GNCA) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Genocea Biosciences has higher revenue and earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
Trevena$443K0.02-$40.29M-$47.04N/A

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Trevena Neutral

Genocea Biosciences has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market. Comparatively, Trevena has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

Trevena's return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
Trevena N/A N/A -119.55%

0.6% of Genocea Biosciences shares are owned by institutional investors. Comparatively, 13.6% of Trevena shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by company insiders. Comparatively, 2.7% of Trevena shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Genocea Biosciences beats Trevena on 5 of the 9 factors compared between the two stocks.

Get Genocea Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for GNCA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GNCA vs. The Competition

Export
MetricGenocea BiosciencesBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$6K$309.61M$6.46B$12.34B
Dividend YieldN/AN/A2.76%5.28%
P/E Ratio0.00N/A21.2225.66
Price / SalesN/A189.70562.2886.31
Price / CashN/A22.4443.4956.67
Price / BookN/A4.7710.317.14
Net Income-$33.20M-$132.96M$3.57B$335.98M

Genocea Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91MN/A70
SCPS
Scopus BioPharma
N/A$0.00
flat		N/AN/A$17KN/AN/A9
ORGS
Orgenesis
N/A$0.00
-93.4%		N/A-68.9%$16K$662KN/A150
VAXX
Vaxxinity
N/A$0.00
-80.0%		N/A+0.0%$13KN/AN/A90
ARDS
Aridis Pharmaceuticals
N/A$0.00
flat		N/A+750.0%$11KN/A0.0030

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:GNCA) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel